Weekly Docetaxel and Prednisolone versus Prednisolone Alone in Androgen-Independent Prostate Cancer: A Randomized Phase II Study
- 31 December 2007
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 52 (6) , 1691-1699
- https://doi.org/10.1016/j.eururo.2007.01.104
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Chemotherapy in Hormone Refractory Prostate Cancer: Where Do We Stand?European Urology, 2004
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004
- Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancerAnnals of Oncology, 2001
- Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostateSeminars in Oncology, 2001
- Flutamide Versus Prednisone in Patients With Prostate Cancer Symptomatically Progressing After Androgen-Ablative Therapy: A Phase III Study of the European Organization for Research and Treatment of Cancer Genitourinary GroupJournal of Clinical Oncology, 2001
- Quality of life assessment in patients with hormone-resistant prostate cancer treated with epirubicin or with epirubicin plus medroxy progesterone acetate - is it feasible?European Urology, 2000
- Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 StudyJournal of Clinical Oncology, 1999
- Phase II trials in the EORTCEuropean Journal Of Cancer, 1997
- Estramustine Phosphate Versus Placebo as Second Line Treatment After Orchiectomy in Patients With Metastatic Prostate Cancer: Daproca Study 9002Journal of Urology, 1997
- Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.Journal of Clinical Oncology, 1996